Join to View Full Profile
3130 Highland AveCincinnati, OH 45219
Phone+1 513-584-4268
Fax+1 513-584-6955
Dr. Curran is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2012 - 2015- University of ChicagoResidency, Internal Medicine, 2008 - 2011
Stanford University School of MedicineClass of 2008
Certifications & Licensure
OH State Medical License 2019 - 2025
IL State Medical License 2011 - 2020
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial.Fieke W Hoff, Ying Huang, Rina Li Welkie, Ronan T Swords, Elie Traer
Blood Cancer Journal. 2025-04-03 - Recognition, prevention, and management of adverse events associated with asparaginase / pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of...Emily Curran, Marlise R Luskin, Houda Alachkar, Ibrahim Aldoss, Patrick W Burke
Haematologica. 2025-03-20 - Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study.Marlise R Luskin, Jun Yin, Gerard Lozanski, Emily Curran, Gregory Malnassy
Cancer. 2025-02-15
Abstracts/Posters
- Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab OzogamicinEmily K Curran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with BlinatumomabEmily K Curran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Ponatinib and Blinatumomab Combination Safe and Effective in Patients with Newly Diagnosed, Ph-Positive ALLFebruary 3rd, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
